Research Program Members
Development and application of powerful proteomic technologies in combination with biochemistry, cell biology and computational analysis to understand the dynamic profiles of the PTM networks in various diseases, and reveal the correlation between cellular metabolism and diverse PTM pathways.
Professor and Director of Graduate Studies
Structural biology research aimed at accelerating the development of medicinal agents and specific inhibitors of drug targets to advance the understanding of disease control, specifically to improve nucleoside pro-drug activation and to discover antagonists of CD44-mediated cell adhesion for improved cancer chemotherapy.
Developing novel targeted therapies and immunotherapy combinations in bladder, prostate and kidney cancers; early phase clinical trials using targeted and immunotherapy agents, including checkpoint inhibitors; the role of androgen receptor (AR) in bladder cancer.
Mechanisms of cancer progression involving signal transduction cross talk with steroid hormone receptors in breast, lung, and ovarian cancer models; role of MAPKs as major inputs to ligand-dependent and -independent progesterone receptor action and target gene selection in breast cancer; role of Brk/PTK6 actions upstream of ERK5 and p37 MAPK stress signalling pathways in breast tumor progression/ hypoxia
Mammary tumor initiation from normal tissue, and signaling of tumor dormancy and recurrence utilizing expertise in 3D organotypic models, molecular tool design for single-cell manipulation, 4D live imaging, and 3D screening platform development
Development of probes and biomarker analysis strategies for detecting therapeutic efficacy with a current focus on companion diagnostics to measure pharmacodynamics of kinase inhibitor drugs in leukemia; development of new directions to use cutting edge proteomics to study oxidative stress and potential prostate (and other) cancer biomarkers.
Modulation of protein-protein interactions of intrinsically disordered proteins by developing chemical probes and structural biology tools for studying the role of these interactions in disease and developing new therapeutics
Potential role for the HIV protease inhibitor, ritonavir, as a modulator of PI2-kinase/AKT signaling in breast cancer and the development of new therapeutic approaches to breast cancer based on its function. Also of interest are the mechanisms of calpain proteases in cell motility and cytoskeletal remodeling.
Natural history of mammary cancer development; identification of molecular and cellular targets of tamoxifen chemoprevention; role of developmental genes in breast carcinogenesis; anticancer gene therapy and utility of mesenchymal stem cells; mouse modeling of cancer to study novel therapeutic and preventive drugs
Professor and Head
Role of growth factors and hormones in the development and growth of lung cancer and the effects of these cytokines on control of tumor growth, their role in risk for cancer, and their signaling pathways; current focus is on estrogen, progesterone, EGF peptides, and hepatocyte growth factor.
Structural insight into the assembly and function of membrane remodeling complexes; molecular mechanisms that control essential intracellular membrane remodeling and trafficking events, such as endo-lysosomal trafficking, apoptosis, autophagy and regulation of mitochondrial dynamics
Professor and Endowed Chair
Rational design of novel anti-cancer therapeutics and nanotechnology based drug delivery systems by employing medicinal organic synthesis, immunology protein engineering, biochemistry and molecular modelling; Characterization of arylamine amine carcinogen metabolizing enzymes
Signal transduction of ATM protein kianses in response to insulin and metformin in both diabetes and cancer; mechanisms of tumor suppressor gene function and cancer development, specifically regulation of p53 induction in response to DNA damage.